Despite the muted success of Sanofi's Dengvaxia in the global market, Globaldata analysts forecast a rosy outlook for Qdenga.
The future of leadership will not be determined by the sophistication of our technologies or the size of our profits, but by the depth of our humanity. The crisis of management today is not merely ...
Two Duke students wanted to work in luxury. So they built the Duke Business of Retail Society. They've not only attracted ...
Avance Clinical, a partner for biotechs providing global contract research organization services, has announced the launch of ...
Introduction Tuberculosis (TB) remains an important public health challenge globally. Madagascar faces a substantial TB burden despite enhanced efforts from its national TB control programme. This ...
Hard work and sacrifice lead to success, and happiness is by-product. In its most productive form, living in a dynamic of ...
A new peer-reviewed study published in the Journal of American College Health provides the first large-scale evidence that ...
At Gartner's annual conference, multiple sessions discussed the challenges of getting a return on investment from AI. Here ...
A Lancet study finds only 40% treatment success for extensively drug-resistant tuberculosis in Europe, with outcomes now ...
In 2025, Japan's digital transformation stands at a crossroads. The "2025 Cliff" proposed by the Ministry of Economy, Trade ...
A new Russian academic study positions Western Sahara as the cornerstone and compass of Morocco's foreign policy identity, ...
The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle stability that one executive described as a “home run.” BridgeBio’s market value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback